| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_883ef14066c153ff611ef557b6c22f71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 |
| filingDate |
2019-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82e2fda39e0cdddec923da9c6d5b03c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae28a459080f660054b0ed6871fe0ae4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2204d39d3eaab673d30631f2b401cbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0f008810e1a71c314ad918dff49a0d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e7f8b2fd8be6c9f60d156d594fa2a4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5ca03d4e5ca2cbb1e7f09c55195997d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc0191dfd1e71a26d8285eaf64964afa |
| publicationDate |
2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019233458-A1 |
| titleOfInvention |
Vegfr inhibitor, preparation method therefor and use thereof |
| abstract |
The present invention relates to a quinoline or quinazoline derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating angiogenesis-associated diseases, in particular for preventing or treating protein tyrosine kinase-associated tumors. Each substituent in formula (I) has the same definition as that in the description. |
| priorityDate |
2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |